Does the media refer more to GUTS or ADCT?

In the previous week, Fractyl Health had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 12 mentions for Fractyl Health and 10 mentions for ADC Therapeutics. Fractyl Health's average media sentiment score of 0.14 beat ADC Therapeutics' score of 0.06 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EVMN or GUTS more profitable?

Evommune's return on equity of -62.63% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Fractyl Health N/A -1,362.10% -84.89%

Does the media refer more to EVMN or GUTS?

In the previous week, Fractyl Health had 10 more articles in the media than Evommune. MarketBeat recorded 12 mentions for Fractyl Health and 2 mentions for Evommune. Fractyl Health's average media sentiment score of 0.14 beat Evommune's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALEC or GUTS more profitable?

Fractyl Health has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Fractyl Health N/A -1,362.10% -84.89%

Does the media prefer ALEC or GUTS?

In the previous week, Fractyl Health had 6 more articles in the media than Alector. MarketBeat recorded 12 mentions for Fractyl Health and 6 mentions for Alector. Alector's average media sentiment score of 0.66 beat Fractyl Health's score of 0.14 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GUTS or AKBA?

In the previous week, Fractyl Health had 8 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Fractyl Health and 4 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.47 beat Fractyl Health's score of 0.14 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fractyl Health (GUTS) Competitors

$4.16 +0.13 (+3.23%)

As of 02:53 PM Eastern

Compare

GUTS vs. ADCT, EVMN, ALEC, AKBA, and PLX

Should you buy Fractyl Health stock or one of its competitors? Fractyl Health's main competitors and comparable companies include ADC Therapeutics (ADCT), Evommune (EVMN), Alector (ALEC), Akebia Therapeutics (AKBA), and Protalix BioTherapeutics (PLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fractyl Health compare to ADC Therapeutics?

Fractyl Health (NASDAQ:GUTS) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Fractyl Health has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Fractyl Health has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$10.56	N/A
ADC Therapeutics	$81.36M	2.64	-$142.62M	-$0.66	N/A

In the previous week, Fractyl Health had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 12 mentions for Fractyl Health and 10 mentions for ADC Therapeutics. Fractyl Health's average media sentiment score of 0.14 beat ADC Therapeutics' score of 0.06 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fractyl Health has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
ADC Therapeutics	-121.77%	N/A	-32.74%

Fractyl Health presently has a consensus price target of $66.00, suggesting a potential upside of 1,537.72%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 196.74%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts clearly believe Fractyl Health is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

41.1% of ADC Therapeutics shares are held by institutional investors. 8.4% of Fractyl Health shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Fractyl Health beats ADC Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Fractyl Health compare to Evommune?

Evommune (NYSE:EVMN) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Evommune presently has a consensus target price of $30.80, suggesting a potential upside of 425.15%. Fractyl Health has a consensus target price of $66.00, suggesting a potential upside of 1,537.72%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.69
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Fractyl Health had 10 more articles in the media than Evommune. MarketBeat recorded 12 mentions for Fractyl Health and 2 mentions for Evommune. Fractyl Health's average media sentiment score of 0.14 beat Evommune's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune's return on equity of -62.63% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Fractyl Health	N/A	-1,362.10%	-84.89%

Evommune has higher revenue and earnings than Fractyl Health. Evommune is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$10M	21.29	-$68.87M	-$11.03	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$10.56	N/A

Summary

Evommune beats Fractyl Health on 7 of the 12 factors compared between the two stocks.

How does Fractyl Health compare to Alector?

Alector (NASDAQ:ALEC) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 8.4% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Fractyl Health had 6 more articles in the media than Alector. MarketBeat recorded 12 mentions for Fractyl Health and 6 mentions for Alector. Alector's average media sentiment score of 0.66 beat Fractyl Health's score of 0.14 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fractyl Health has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Fractyl Health	N/A	-1,362.10%	-84.89%

Alector currently has a consensus target price of $3.40, indicating a potential upside of 81.82%. Fractyl Health has a consensus target price of $66.00, indicating a potential upside of 1,537.72%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alector has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market.

Fractyl Health has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.92	-$142.93M	-$1.10	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$10.56	N/A

Summary

Fractyl Health beats Alector on 7 of the 13 factors compared between the two stocks.

How does Fractyl Health compare to Akebia Therapeutics?

Fractyl Health (NASDAQ:GUTS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Fractyl Health has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Fractyl Health presently has a consensus price target of $66.00, suggesting a potential upside of 1,537.72%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 406.49%. Given Fractyl Health's higher probable upside, equities analysts plainly believe Fractyl Health is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

33.9% of Akebia Therapeutics shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Akebia Therapeutics has higher revenue and earnings than Fractyl Health. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$10.56	N/A
Akebia Therapeutics	$236.20M	0.90	-$5.34M	-$0.11	N/A

In the previous week, Fractyl Health had 8 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Fractyl Health and 4 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.47 beat Fractyl Health's score of 0.14 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fractyl Health has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Summary

Akebia Therapeutics beats Fractyl Health on 9 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Fractyl Health had 12 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 12 mentions for Fractyl Health and 0 mentions for Protalix BioTherapeutics. Fractyl Health's average media sentiment score of 0.14 beat Protalix BioTherapeutics' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Fractyl Health	Neutral

Protalix BioTherapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Fractyl Health has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Fractyl Health	N/A	-1,362.10%	-84.89%

Protalix BioTherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 336.36%. Fractyl Health has a consensus target price of $66.00, suggesting a potential upside of 1,537.72%. Given Fractyl Health's higher possible upside, analysts plainly believe Fractyl Health is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Protalix BioTherapeutics has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.75	$8.31M	$0.23	11.96
Fractyl Health	N/A	N/A	-$140.95M	-$10.56	N/A

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 8.4% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Fractyl Health beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.46M	$3.91B	$7.28B	$12.93B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.38	12.99	275.40	25.27
Price / Sales	N/A	1,152.92	562.90	78.90
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	4.87	16.61	10.55	5.93
Net Income	-$140.95M	-$22.69M	$3.50B	$380.91M
7 Day Performance	-10.62%	-6.02%	-3.94%	-4.21%
1 Month Performance	-44.81%	-13.82%	-8.33%	-7.05%
1 Year Performance	-75.06%	6.88%	2.44%	-4.87%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	2.7303 of 5 stars	$4.16 +3.2%	$66.00 +1,486.5%	-74.9%	$55.16M	N/A	N/A	73
ADCT ADC Therapeutics	1.826 of 5 stars	$1.82 +14.2%	$5.00 +175.5%	-63.6%	$231.72M	$79.58M	N/A	191
EVMN Evommune	2.342 of 5 stars	$6.40 -0.2%	$33.33 +420.8%	N/A	$230.88M	$13M	N/A	48	Analyst Upgrade
ALEC Alector	2.1781 of 5 stars	$2.08 +2.7%	$3.40 +63.9%	-38.5%	$229.46M	$13.86M	N/A	103	Analyst Forecast
AKBA Akebia Therapeutics	2.3062 of 5 stars	$0.82 +0.5%	$3.90 +376.2%	-72.3%	$226.95M	$236.20M	N/A	194	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. ADCT, EVMN, ALEC, AKBA, and PLX

How does Fractyl Health compare to ADC Therapeutics?

Summary

How does Fractyl Health compare to Evommune?

Summary

How does Fractyl Health compare to Alector?

Summary

How does Fractyl Health compare to Akebia Therapeutics?

Summary

How does Fractyl Health compare to Protalix BioTherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. ADCT, EVMN, ALEC, AKBA, and PLX

How does Fractyl Health compare to ADC Therapeutics?

Which has more risk & volatility, GUTS or ADCT?

Which has higher earnings & valuation, GUTS or ADCT?

Does the media refer more to GUTS or ADCT?

Is GUTS or ADCT more profitable?

Do analysts recommend GUTS or ADCT?

Do insiders & institutionals have more ownership in GUTS or ADCT?

Summary

How does Fractyl Health compare to Evommune?

Do analysts recommend EVMN or GUTS?

Does the media refer more to EVMN or GUTS?

Is EVMN or GUTS more profitable?

Which has better valuation & earnings, EVMN or GUTS?

Summary

How does Fractyl Health compare to Alector?

Do institutionals & insiders believe in ALEC or GUTS?

Does the media prefer ALEC or GUTS?

Is ALEC or GUTS more profitable?

Do analysts rate ALEC or GUTS?

Which has more risk & volatility, ALEC or GUTS?

Which has stronger earnings and valuation, ALEC or GUTS?

Summary

How does Fractyl Health compare to Akebia Therapeutics?

Which has more volatility & risk, GUTS or AKBA?

Do analysts rate GUTS or AKBA?

Do insiders & institutionals have more ownership in GUTS or AKBA?

Which has preferable earnings & valuation, GUTS or AKBA?

Does the media favor GUTS or AKBA?

Is GUTS or AKBA more profitable?

Summary

How does Fractyl Health compare to Protalix BioTherapeutics?

Does the media prefer PLX or GUTS?

Which has more risk and volatility, PLX or GUTS?

Is PLX or GUTS more profitable?

Do analysts rate PLX or GUTS?

Which has higher valuation & earnings, PLX or GUTS?

Do institutionals and insiders hold more shares of PLX or GUTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools